Jillian P Casey1,2, Suzanne Slattery3, Melanie Cotter4, A A Monavari3, Ina Knerr3, Joanne Hughes3, Eileen P Treacy3, Deirdre Devaney5, Michael McDermott6, Eoghan Laffan7, Derek Wong8, Sally Ann Lynch1,2,9, Billy Bourke10, Ellen Crushell11,12,13. 1. Genetics Department, Temple Street Children's University Hospital, Dublin 1, Ireland. 2. UCD Academic Centre on Rare Diseases, School of Medicine and Medical Science, University College Dublin, Belfield, Dublin 4, Ireland. 3. National Centre for Inherited Metabolic Disorders, Temple Street Children's University Hospital, Dublin 1, Ireland. 4. Department of Haematology, Temple Street Children's University Hospital, Dublin 1, Ireland. 5. Histopathology Department, Temple Street Children's University Hospital, Dublin 1, Ireland. 6. Pathology Department, Our Lady's Children's Hospital, Crumlin, Dublin 12, Ireland. 7. Department of Radiology, Temple Street Children's University Hospital, Dublin 1, Ireland. 8. Department of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA. 9. National Centre for Medical Genetics, Our Lady's Children's Hospital, Crumlin, Dublin 12, Ireland. 10. Our Lady's Children's Hospital, Crumlin, Dublin 12, Ireland. 11. UCD Academic Centre on Rare Diseases, School of Medicine and Medical Science, University College Dublin, Belfield, Dublin 4, Ireland. ellen.crushell@cuh.ie. 12. National Centre for Inherited Metabolic Disorders, Temple Street Children's University Hospital, Dublin 1, Ireland. ellen.crushell@cuh.ie. 13. Our Lady's Children's Hospital, Crumlin, Dublin 12, Ireland. ellen.crushell@cuh.ie.
Abstract
BACKGROUND: Recessive LARS mutations were recently reported to cause a novel syndrome, infantile liver failure syndrome type 1 (ILFS1), in six Irish Travellers. We have since identified four additional patients, including one of Ashkenazi origin, representing the largest ILFS1 cohort to date. Our study aims to define the ILFS1 clinical phenotype to help guide diagnosis and patient management. METHODS: We clinically evaluated and reviewed the medical records of ten ILFS1 patients. Clinical features, histopathology and natural histories were compared and patient management strategies reviewed. RESULTS: Early failure to thrive, recurrent liver dysfunction, anemia, hypoalbuminemia and seizures were present in all patients. Most patients (90 %) had developmental delay. Encephalopathic episodes triggered by febrile illness have occurred in 80 % and were fatal in two children. Two patients are currently >28 years old and clinically well. Leucine supplementation had no appreciable impact on patient well-being. However, we suggest that the traditional management of reducing/stopping protein intake in patients with metabolic hepatopathies may not be appropriate for ILFS1. We currently recommend ensuring sufficient natural protein intake when unwell. CONCLUSIONS: We report the first non-Irish ILFS1 patient, suggesting ILFS1 may be more extensive than anticipated. Low birth weight, early failure to thrive, anemia and hypoalbuminemia are amongst the first presenting features, with liver dysfunction before age 1. Episodic hepatic dysfunction is typically triggered by febrile illness, and becomes less severe with increasing age. While difficult to anticipate, two patients are currently >28 years old, suggesting that survival beyond childhood may be associated with a favourable long-term prognosis.
BACKGROUND: Recessive LARS mutations were recently reported to cause a novel syndrome, infantile liver failure syndrome type 1 (ILFS1), in six Irish Travellers. We have since identified four additional patients, including one of Ashkenazi origin, representing the largest ILFS1 cohort to date. Our study aims to define the ILFS1 clinical phenotype to help guide diagnosis and patient management. METHODS: We clinically evaluated and reviewed the medical records of ten ILFS1 patients. Clinical features, histopathology and natural histories were compared and patient management strategies reviewed. RESULTS: Early failure to thrive, recurrent liver dysfunction, anemia, hypoalbuminemia and seizures were present in all patients. Most patients (90 %) had developmental delay. Encephalopathic episodes triggered by febrile illness have occurred in 80 % and were fatal in two children. Two patients are currently >28 years old and clinically well. Leucine supplementation had no appreciable impact on patient well-being. However, we suggest that the traditional management of reducing/stopping protein intake in patients with metabolic hepatopathies may not be appropriate for ILFS1. We currently recommend ensuring sufficient natural protein intake when unwell. CONCLUSIONS: We report the first non-Irish ILFS1 patient, suggesting ILFS1 may be more extensive than anticipated. Low birth weight, early failure to thrive, anemia and hypoalbuminemia are amongst the first presenting features, with liver dysfunction before age 1. Episodic hepatic dysfunction is typically triggered by febrile illness, and becomes less severe with increasing age. While difficult to anticipate, two patients are currently >28 years old, suggesting that survival beyond childhood may be associated with a favourable long-term prognosis.
Authors: Jillian P Casey; Paul McGettigan; Niamh Lynam-Lennon; Michael McDermott; Regina Regan; Judith Conroy; Billy Bourke; Jacintha O'Sullivan; Ellen Crushell; SallyAnn Lynch; Sean Ennis Journal: Mol Genet Metab Date: 2012-04-26 Impact factor: 4.797
Authors: Atsushi Umemura; Eek Joong Park; Koji Taniguchi; Jun Hee Lee; Shabnam Shalapour; Mark A Valasek; Mariam Aghajan; Hayato Nakagawa; Ekihiro Seki; Michael N Hall; Michael Karin Journal: Cell Metab Date: 2014-06-05 Impact factor: 27.287
Authors: Eline van Meel; Daniel J Wegner; Paul Cliften; Marcia C Willing; Frances V White; Stuart Kornfeld; F Sessions Cole Journal: BMC Med Genet Date: 2013-10-08 Impact factor: 2.103
Authors: Robert Kopajtich; Kei Murayama; Andreas R Janecke; Tobias B Haack; Maximilian Breuer; A S Knisely; Inga Harting; Toya Ohashi; Yasushi Okazaki; Daisaku Watanabe; Yoshimi Tokuzawa; Urania Kotzaeridou; Stefan Kölker; Sven Sauer; Matthias Carl; Simon Straub; Andreas Entenmann; Elke Gizewski; René G Feichtinger; Johannes A Mayr; Karoline Lackner; Tim M Strom; Thomas Meitinger; Thomas Müller; Akira Ohtake; Georg F Hoffmann; Holger Prokisch; Christian Staufner Journal: Am J Hum Genet Date: 2016-07-14 Impact factor: 11.025
Authors: Christina Peroutka; Jacqueline Salas; Jacquelyn Britton; Juliet Bishop; Lisa Kratz; Maureen M Gilmore; Jill A Fahrner; W Christopher Golden; Tao Wang Journal: JIMD Rep Date: 2018-10-23
Authors: Rawah K H M Zeiad; Edwin C Ferren; Denise D Young; Shanelle J De Lancy; Demitrios Dedousis; Lori-Anne Schillaci; Raymond W Redline; Shahrazad T Saab; Maricruz Crespo; Tricia R Bhatti; Amanda M Ackermann; Jirair K Bedoyan; Jamie R Wood Journal: J Endocr Soc Date: 2021-01-02
Authors: Imre F Schene; Gautam Kok; Sabine A Fuchs; Jurriaan M Jansen; Peter G J Nikkels; Koen L I van Gassen; Suzanne W J Terheggen-Lagro; Saskia N van der Crabben; Sanne E Hoeks; Laetitia E M Niers; Nicole I Wolf; Maaike C de Vries; David A Koolen; Roderick H J Houwen; Margot F Mulder; Peter M van Hasselt Journal: Genet Med Date: 2018-06-06 Impact factor: 8.822